Dr. Allen is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5607 W 125th St
Overland Park, KS 66209Phone+1 816-729-7801
Summary
- Dr. Ace Allen is a retired oncology specialist. He completed his initial medical education and further specializations in Internal Medicine and Medical Oncology at the University of Kansas School of Medicine. He retired in 2021 from his position as Staff Oncologist at Topeka's Colmery-O'Neil VAMC. Dr. Allen has made considerable contributions to oncology, healthcare, and telemedicine research, with several of his publications being cited multiple times. With the help of a Career Development Award from the NCI's Division of Cancer Prevention and Control, he did pioneering telemedicine research in efficacy, user satisfaction, cost-benefit, and rural applications. In oncology, he published papers on head and neck, lung, and prostate cancer.
Education & Training
University of Kansas School of MedicineFellowship, Hematology and Medical Oncology, 1986 - 1988- University of Kansas School of MedicineResidency, Internal Medicine, 1983 - 1986
- University of Kansas School of MedicineClass of 1983
Certifications & Licensure
KS State Medical License 1984 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer Start of enrollment: 2013 Mar 08
Publications & Presentations
PubMed
- 4 citationsPositivity Rates in Oropharyngeal and Nonoropharyngeal Head and Neck Cancer in the VA.John L. Park, Veronica McPike, Suman Kambhampati, Chao Huang, January Fields-Meehan
Federal Practitioner. 2018-08-01 - 8 citationsImpact Study: MK-0646 (Dalotuzumab), Insulin Growth Factor 1 Receptor Antibody Combined with Pemetrexed and Cisplatin in Stage IV Metastatic Non-squamous Lung Cancer.Chao H. Huang, Stephen K. Williamson, Prakash Neupane, Sarah A. Taylor, Ace Allen
Frontiers in Oncology. 2016-01-13 - 12 citationsPotential Role of Platelet-Derived Growth Factor Receptor Inhibition Using Imatinib in Combination with Docetaxel in the Treatment of Recurrent Non-small Cell Lung CancerChao H. Huang, Stephen K. Williamson, Peter J. Van Veldhuizen, Chung-Tsen Hsueh, Ace Allen
Journal of Thoracic Oncology. 2011-02-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
